Effect of Bifidobacterium longum on cognition and microbiota in post-stroke patients: a single-blinded, controlled trial.

Bifidobacterium longum OLP-01 supplementation improved overall cognitive function as measured by MoCA scores in post-stroke patients.

• The OLP-01 group showed increased MoCA scores over the 12-week intervention period.
• Participants received 2 × 10^10 CFU of Bifidobacterium longum OLP-01 powder daily for 12 weeks.
• The study was a single-blinded, randomized, placebo-controlled trial with 12 participants in the OLP-01 group and 10 in the placebo group.
• MoCA (Montreal Cognitive Assessment) was used as a primary outcome measure for cognitive function.

Bifidobacterium longum OLP-01 supplementation improved executive function as measured by Trail-Making Tests in post-stroke patients.

• The OLP-01 group demonstrated decreased time to completion of Trail-Making Tests compared to the placebo group.
• Trail-Making Tests were used as one of the primary cognitive outcome measures.
• The intervention lasted 12 weeks at a dose of 2 × 10^10 CFU daily.

Bifidobacterium longum OLP-01 supplementation improved cognitive inhibition control as measured by the Stroop Color Naming Test in post-stroke patients.

• The OLP-01 group had greater accuracy on the incongruent condition of the Stroop Color Naming Test.
• The incongruent condition of the Stroop test measures cognitive interference and inhibitory control.
• This was assessed as a primary cognitive outcome measure alongside MoCA and Trail-Making Tests.

Bifidobacterium longum OLP-01 supplementation was associated with changes in cognitive-related gut microbiota strains in post-stroke patients.

• Cognitive-related gut microbiota strains showed differences between the OLP-01 group and the placebo group.
• Gut microbiota analysis was designated as a primary outcome of the study.
• Blood and stool samples were collected for biochemical and gut microbiota analyses.
• The probiotic used, Bifidobacterium longum OLP-01, was sourced from an Olympics gold medalist.

Bifidobacterium longum OLP-01 supplementation did not improve physical performance in post-stroke patients.

• Physical performance was measured using the Timed Up and Go Test and the 6-Minute Walk Test.
• No significant differences in physical performance were observed between the OLP-01 group and placebo group.
• Physical performance was assessed as a secondary outcome of the study.
• The intervention was 12 weeks in duration at 2 × 10^10 CFU daily.

Bifidobacterium longum OLP-01 supplementation was associated with decreased MNA scores, though scores remained within normal ranges.

• The OLP-01 group showed decreased Mini Nutritional Assessment (MNA) scores during the intervention.
• Despite the decrease, MNA scores remained within normal ranges.
• Nutritional status was assessed as a secondary outcome using the Mini Nutritional Assessment (MNA).
• The clinical significance of this finding within normal MNA ranges is limited.

The study population consisted of post-stroke patients with malnutrition, cognitive dysfunction, motor impairment, and gut dysbiosis as observed comorbidities.

• A total of 22 post-stroke patients were recruited for the trial.
• Participants were randomized to either placebo (n = 10) or OLP-01 (n = 12) groups.
• The study design was a single-blinded, randomized, placebo-controlled trial.
• Stroke is described as a major leading cause of death globally with a high disability rate.